Auriga Research Pvt. Ltd. has received an FDA Warning Letter after a February 2026 inspection of its contract testing laboratory in Bengaluru, India. FDA cited significant CGMP violations involving incomplete laboratory records, weak Quality Unit oversight, and OOS investigations based
